Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Mod Pathol. 2019 Feb;32(2):205-215. doi: 10.1038/s41379-018-0126-3. Epub 2018 Sep 11.
IDH2 R172 mutations occur in >80% sinonasal undifferentiated carcinomas ("SNUC") and ~80% of these are R172S and R172T variants. We examined the utility of the monoclonal antibody 11C8B1 to IDH2 R172S in IDH2 R172-mutated tumors to establish an immunohistochemistry protocol as a surrogate method for IDH2 R172S mutation detection. Eighty-eight formalin-fixed paraffin-embedded tumors including 42 sinonasal tumors and a variety of IDH1/2-mutated malignancies were tested by immunohistochemistry. The IDH1/2 mutation status was determined in 86 cases by a targeted massively parallel sequencing MSK-IMPACT assay. Interestingly, monoclonal antibody 11C8B1 was reactive with all IDH2 R172S (N = 15) mutated tumors including 12 sinonasal carcinomas, 2 high-grade sarcomas and one intrahepatic cholangiocarcinoma, and with all R172T (N = 3) mutated sinonasal carcinomas displaying a distinct granular cytoplasmic labeling in all R172S/T mutated malignancies. 11C8B1 immunohistochemistry was also positive in 2 of 6 IDH1 R132S-mutated tumors, including one intrahepatic cholangiocarcinoma and one chondrosarcoma showing a smooth homogeneous cytoplasmic staining pattern. All IDH2 R172G/K/M/W (N = 22) and IDH1 132H/C/G/L (N = 15) mutated tumors, and all IDH1/2-wild-type tumors (N = 25), including a histologic variety of 23 sinonasal tumors, were immunonegative. Importantly, 11 sinonasal undifferentiated carcinomas (N = 14, 79%) and 3 (100%) high-grade neuroendocrine carcinomas, large cell type were 11C8B1 immunopositive. Literature search revealed a virtual absence of IDH2 R172 and IDH1 R132S mutations in >1000 cases of 8 different malignancies included in the differential diagnosis of sinonasal undifferentiated carcinoma. Our study suggests that positive IDH2 11C8B1 immunohistochemistry in sinonasal carcinomas would be highly predictive of the presence of IDH2 R172S/T mutations and could serve as a reliable adjunct diagnostic marker of sinonasal undifferentiated carcinomas in >70% cases.
IDH2 R172 突变发生在>80%的鼻腔鼻窦未分化癌(“SNUC”)中,其中约 80%为 R172S 和 R172T 变体。我们研究了单克隆抗体 11C8B1 对 IDH2 R172S 突变肿瘤的用途,以建立免疫组织化学检测方法作为 IDH2 R172S 突变检测的替代方法。使用免疫组织化学方法检测了包括 42 例鼻腔鼻窦肿瘤和多种 IDH1/2 突变恶性肿瘤在内的 88 例福尔马林固定石蜡包埋肿瘤。通过靶向大规模平行测序 MSK-IMPACT 检测确定 86 例 IDH1/2 突变状态。有趣的是,单克隆抗体 11C8B1 与所有 IDH2 R172S(N=15)突变肿瘤反应,包括 12 例鼻腔鼻窦癌、2 例高级别肉瘤和 1 例肝内胆管癌,以及所有 R172T(N=3)突变的鼻腔鼻窦癌在所有 R172S/T 突变的恶性肿瘤中均显示出独特的颗粒状细胞质标记。在 6 例 IDH1 R132S 突变肿瘤中,有 2 例(包括 1 例肝内胆管癌和 1 例软骨肉瘤)的 11C8B1 免疫组化呈阳性,呈光滑均匀的细胞质染色模式。所有 IDH2 R172G/K/M/W(N=22)和 IDH1 132H/C/G/L(N=15)突变肿瘤以及所有 IDH1/2 野生型肿瘤(N=25),包括 23 例鼻腔鼻窦肿瘤的多种组织学类型,均为免疫阴性。重要的是,11 例鼻腔鼻窦未分化癌(N=14,79%)和 3 例(100%)高级别神经内分泌癌,大细胞型 11C8B1 免疫阳性。文献检索显示,在纳入鼻腔鼻窦未分化癌鉴别诊断的 8 种不同恶性肿瘤的>1000 例中,几乎不存在 IDH2 R172 和 IDH1 R132S 突变。我们的研究表明,鼻腔鼻窦癌中 IDH2 11C8B1 免疫组化阳性高度提示存在 IDH2 R172S/T 突变,可作为>70%病例中鼻腔鼻窦未分化癌可靠的辅助诊断标志物。